Tag:
Lemtrada
Latest Headlines
Latest Headlines
Sanofi's Lemtrada beats Rebif in head-to-head MS showdown
Sanofi has rolled out a fresh set of late-stage Lemtrada (alemtuzumab) data demonstrating its superiority to Rebif in a head-to-head matchup for multiple sclerosis.
UPDATED: Sanofi CEO touts partnership drugs as pipeline standouts
Viehbacher told the BBJ that he'd like to see a 50-50 ratio of external and internal R&D programs at his company.
Biogen Idec races to FDA and EMA with a blockbuster app for BG-12
Biogen Idec has filed an NDA on BG-12 , another step in its blockbuster quest to gain an approval on its best near-term hope for a game-changing new treatment.
Is Sanofi destined to be 'small player' in MS?
Sanofi ( $SNY ) CEO Chris Viehbacher ( photo ) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme . But advances by other companies are making it
Sanofi chief can't spark much enthusiasm for new MS drugs
Back when Sanofi's Chris Viehbacher was in the hunt for Genzyme, one of the big sticking points was assessing the value of the experimental MS drug Lemtrada . Genzyme's forecasts were starry eyed.
Sanofi boasts superior relapse-free rate for Lemtrada in MS study
Sanofi ( $SNY )and Genzyme ( $GENZ ) never could agree on peak sales estimates on Lemtrada, the Boston biotech's late-stage oral therapy for MS, when the two negotiated over buyout terms. Over the
Sanofi lines up a growing slate of late-stage drug prospects
Few Big Pharma companies have done as much as Sanofi to change the game plan in R&D. And if you drill down into the company's second quarter report today, you'll find a snapshot of just how
Sanofi MS drug shines, biotech strategy advances
Sanofi is seeing its increased focus on biotech drugs go according to plan, with positive results today from a late-stage trial of a multiple sclerosis treatment, Lemtrada, which the French drugmaker
